{
    "code": "20000015",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=20000015",
    "time": "2020-02-26 03:04:47",
    "許可證字號": "衛署罕藥輸字第000015號",
    "註銷狀態": "已註銷",
    "註銷日期": "108\/03\/14",
    "註銷理由": "未展延而逾期者",
    "有效日期": "105\/12\/21",
    "發證日期": "95\/12\/21",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA02000001508",
    "中文品名": "可舒鬆注射液20公絲",
    "英文品名": "Copaxone 20mg Solution for Injection",
    "適應症": "copaxone用於治療首次出現臨床症狀且有MRI為佐證之多發性硬化症病人。復發型多發性硬化症Copaxone，用於減少復發型多發性硬化症病人的復發頻率。",
    "劑型": "270注射劑",
    "包裝": "1ml注射針筒 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "藥品分類": "",
    "主製造廠": {
        "限制項目": "02輸　入 1Q不得輸入",
        "申請商名稱": "1011101100  海喬國際股份有限公司",
        "申請商地址": "台北市大同區重慶北路三段276號9樓",
        "主製造廠": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200043510",
            "成分名稱": "GLATIRAMER ACETATE",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "200000150013.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=20000015&Seq=029&Type=9"
        },
        {
            "title": "200000150005.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=20000015&Seq=005&Type=8"
        }
    ]
}